v3.26.1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva Shareholders' Equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2022 $ 8,598 $ 57 $ 27,688 $ (12,975) $ (2,838) $ (4,128) $ 7,804 $ 794
Beginning balance, shares at Dec. 31, 2022   1,217            
Net income (loss) (615)     (559)       (56)
Net income (loss) (559)           (559)  
Other comprehensive income (loss) 91       141   141 (50)
Other comprehensive income (loss) [1]         141      
Issuance of shares, shares   10            
Stock-based compensation expense 121   121       121  
Dividend to non-controlling interests [2] (68)             (68)
Ending balance at Dec. 31, 2023 8,126 $ 57 27,807 (13,534) (2,697) (4,128) 7,506 620
Ending balance, shares at Dec. 31, 2023   1,227            
Net income (loss) (1,959)     (1,639)       (320)
Net income (loss) (1,639)           (1,639)  
Other comprehensive income (loss) (508)       (447)   (447) (61)
Other comprehensive income (loss) [1]         (450)      
Issuance of shares, value 1 $ 1         1  
Issuance of shares, shares   13            
Stock-based compensation expense 123   123       123  
Dividend to non-controlling interests [2] (18)             (18)
Proceeds from exercise of options 19   19       19  
Purchase of shares from non-controlling interests [3] (64)   (45)   (3)   (48) (16)
Reclassification to redeemable non-controlling interests [4] (340)   (142)       (142) (198)
Ending balance at Dec. 31, 2024 5,380 $ 58 27,764 (15,173) (3,148) (4,128) 5,373 7
Ending balance, shares at Dec. 31, 2024   1,240            
Net income (loss) 1,411     1,410       1
Net income (loss) 1,410           1,410  
Other comprehensive income (loss) 784              
Other comprehensive income (loss) 757       757 [1]   757  
Issuance of shares, value 1           1  
Issuance of shares, shares   16            
Stock-based compensation expense 157   157       157  
Dividend to non-controlling interests [5] (4)             (4)
Proceeds from exercise of options 47   47       47  
Purchase of shares from non-controlling interests (38)              
Purchase of shares from redeemable non-controlling interests [4] 165   165       165  
Ending balance at Dec. 31, 2025 $ 7,914 $ 58 $ 28,133 $ (13,762) $ (2,391) $ (4,128) $ 7,910 $ 4
Ending balance, shares at Dec. 31, 2025   1,256            
[1] Amounts do not include $27 million gain in 2025, $61 million loss in 2024 and $50 million loss in 2023 from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests.
[2] Mainly in connection with a declaration of dividends to non-controlling interests in Teva’s business venture in Japan.
[3] Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland.
[4] In connection with the sale of Teva’s business venture in Japan. See note 22.
[5] In connection with a declaration of dividends to non-controlling interests in Teva’s subsidiary in Bulgaria.